Literature DB >> 30076661

The impact of breast MRI workup on tumor size assessment and surgical planning in patients with early breast cancer.

Catalin-Florin Pop1, Claudia Stanciu-Pop2, Stylianos Drisis3, Magali Radermeker3, Carine Vandemerckt3, Danielle Noterman1, Michel Moreau4, Denis Larsimont5, Jean-Marie Nogaret1, Isabelle Veys1.   

Abstract

BACKGROUND: The size and focality of the primary tumor in breast cancer (BC) influence therapeutic decision making. The purpose of this study was to evaluate whether preoperative breast magnetic resonance imaging (MRI) is helpful for the assessment of tumor size and surgical planning in early BC.
METHODS: We performed a retrospective review of a prospectively collected database of 174 patients treated at a single institution for invasive BC who had complete documentation of the tumor size from mammography (MMG), ultrasonography (US), and MRI.
RESULTS: A total of 186 breast tumors were analyzed. Mean tumor size varied by imaging method: 14.7 mm by MMG, 13.8 mm by US, and 17.9 mm by MRI. The concordance between breast imaging techniques (BIT) and final pathology with a cutoff ≤ 2 mm was 34.8% for MRI, 32.1% for US, and 27.2% for MMG. US and MMG underestimated while MRI and MMG overestimated the real tumor size. Concordance was the same in premenopausal women for MRI and US at 35%, while concordance was higher in postmenopausal women for MRI. Correlations between size determined by BIT and histopathological size were best with MRI (0.59), compared to US (0.56) or MMG (0.42). Intrinsic subtypes of BC had different concordances according to imaging method, but no significant associations were found. MRI examination revealed additional lesions in 13.8% of patients, 69% of these lesions were malignant. MRI changed the surgical plan in 15 patients (8.6%), and the rate of mastectomy increased by 6.9%.
CONCLUSIONS: MRI estimates BC tumor size more accurately than US or MMG, but a significant overestimation exists. Complementary MRI examination improved the concordance for tumor size between BIT and final pathology in 16.7%. MRI did not alter surgical planning for most patients and allowed more appropriate treatment for 8% of them.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  MRI; breast cancer; pathology; surgical treatment; tumor size

Mesh:

Year:  2018        PMID: 30076661     DOI: 10.1111/tbj.13104

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  5 in total

1.  Contrast enhanced digital mammography versus magnetic resonance imaging for accurate measurement of the size of breast cancer.

Authors:  Inyoung Youn; SeonHyeong Choi; Yoon Jung Choi; Ju Hee Moon; Hee Jin Park; Soo-Youn Ham; Chan Heun Park; Eun Young Kim; Shin Ho Kook
Journal:  Br J Radiol       Date:  2019-04-24       Impact factor: 3.039

2.  Comparison of Diagnostic Efficacy Between Contrast-Enhanced Ultrasound and DCE-MRI for Mass- and Non-Mass-Like Enhancement Types in Breast Lesions.

Authors:  Wei Liu; Min Zong; Hai-Yan Gong; Li-Jun Ling; Xin-Hua Ye; Shui Wang; Cui-Ying Li
Journal:  Cancer Manag Res       Date:  2020-12-31       Impact factor: 3.989

3.  MRI-Derived Tumour-to-Breast Volume Is Associated with the Extent of Breast Surgery.

Authors:  Andrea Cozzi; Simone Schiaffino; Gianmarco Della Pepa; Serena Carriero; Veronica Magni; Diana Spinelli; Luca A Carbonaro; Francesco Sardanelli
Journal:  Diagnostics (Basel)       Date:  2021-01-30

4.  Deep learning-based automatic segmentation for size and volumetric measurement of breast cancer on magnetic resonance imaging.

Authors:  Wenyi Yue; Hongtao Zhang; Juan Zhou; Guang Li; Zhe Tang; Zeyu Sun; Jianming Cai; Ning Tian; Shen Gao; Jinghui Dong; Yuan Liu; Xu Bai; Fugeng Sheng
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

5.  Agreement between dynamic contrast-enhanced magnetic resonance imaging and pathologic tumour size of breast cancer and analysis of the correlation with BI-RADS descriptors.

Authors:  Aysegul Akdogan Gemici; Ercan Inci
Journal:  Pol J Radiol       Date:  2019-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.